Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | FCER2 | P06734 | 3/20 | 0.50 |
| ▸ | MMP1 | P03956 | 2/20 | 0.50 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.49 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.49 |
| ▸ | GHSR | Q92847 | 1/20 | 0.48 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.48 |
| ▸ | FURIN | P09958 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845647 | 0.91 | GHSR (0.55) | GNPATCTSLGHSRFURIN | |
| SCHEMBL18499711 | 0.91 | GHSR (0.55) | GNPATCTSLGHSRFURIN | |
| SCHEMBL15499735 | 0.90 | GNPAT (0.55) | GNPATCTSLMMP1NPFFR1NPFFR2 | |
| SCHEMBL17550583 | 0.88 | FCER2 (0.57) | GNPATCTSLFCER2MMP1 | |
| SCHEMBL20159738 | 0.86 | MMP2 (0.57) | GNPATMMP1 | |
| SCHEMBL22695740 | 0.86 | GNPAT (0.54) | GNPATMMP1GHSRFURIN | |
| SCHEMBL15948101 | 0.86 | GNPAT (0.54) | GNPATMMP1GHSRFURIN | |
| SCHEMBL21788139 | 0.85 | GNPAT (0.53) | GNPATMMP1GHSR | |
| SCHEMBL5703555 | 0.85 | PRSS1 (0.59) | CTSLFCER2 | |
| SCHEMBL14553984 | 0.85 | GNPAT (0.48) | GNPATCTSLMMP1NPFFR1NPFFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526239-B1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORP (KR) | 2021-11-03 | — | — | EP | disclosed |
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2019-11-14 | — | — | US | disclosed |
| WO-2018069764-A1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | AR, NR5A1, NR5A2 | GNPAT 2278/4885CTSL 3909/4885FCER2 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.